Financing ·
Candel Therapeutics reports positive Phase 3 results for aglatimagene in prostate cancer
CADLCandel Therapeutics, Inc.
Candel Therapeutics, Inc. filed an 8-K on September 9, 2026, to furnish an investor presentation under Regulation FD. The presentation highlights positive Phase 3 results for aglatimagene in prostate cancer and Phase 2a data for NSCLC and pancreatic cancer. It confirms a $130 million term loan with Trinity Capital (October 2025) and a $100 million royalty funding agreement with RTW Investments (February 2026). The company reported $201.6 million in cash as of June 30, 2026, providing runway into Q1 2028. Candel Therapeutics operates in the biotechnology industry, developing immunotherapies for cancer.